U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H53N7O5S2
Molecular Weight 776.023
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of COBICISTAT

SMILES

CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5)=CS1

InChI

InChIKey=ZCIGNRJZKPOIKD-CQXVEOKZSA-N
InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1

HIDE SMILES / InChI
Molecular Formula C40H53N7O5S2
Molecular Weight 776.023
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/tybost/tybost_pi.pdf | https://www.ncbi.nlm.nih.gov/pubmed/23471741

Cobicistat (GS-9350) is a potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes. Cobicistat is a pharmacokinetic booster of several antiretrovirals. TYBOST (cobicistat) is indicated to increase systemic exposure of atazanavir or darunavir in combination with other antiretroviral agents in the treatment of HIV-1 infection.

Originator

Approval Year

2012
608
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
TYBOST

Approved Use

TYBOST (cobicistat) indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection.

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.99 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203094s008lbl.pdf
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Atazanavir
Atazanavir
 COBICISTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7.6 mg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203094s008lbl.pdf
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Atazanavir
Atazanavir
 COBICISTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203094s008lbl.pdf
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Atazanavir
Atazanavir
 COBICISTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203094s008lbl.pdf
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: Atazanavir
Atazanavir
 COBICISTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
300 mg 1 times / day steady, oral
Highest studied dose
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20043009
healthy, 27 years (range: 18–45 years)
Health Status: healthy
Age Group: 27 years (range: 18–45 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/20043009
Sources:
https://pubmed.ncbi.nlm.nih.gov/20043009
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/20043009
healthy, 27 years (range: 18–45 years)
Health Status: healthy
Age Group: 27 years (range: 18–45 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/20043009
Sources:
https://pubmed.ncbi.nlm.nih.gov/20043009
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inducer
1087
inhibitor
2438

inducer
440
substrate
1388

inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP3A
227

CYP1A2
2153

CYP2B6
926

CYP2C8
1057

CYP2C19
2057

UGT1A1
246

P-gp
1741

BCRP
910

OAT1
725

OAT3
747

MRP4
290

OCT2
779

OATP1B1
1079

OATP1B3
961
P-gp
2052

BCRP
697
CYP2C19
329

CYP1A2
832

CYP2B6
669

CYP2C8
198

UGT1A1
78

P-gp
301
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OATP1B3
970
 likely [IC50 1.88 uM]
OATP1B1
1095
 likely [IC50 3.5 uM]
CYP1A2
2333
 no
CYP2B6
1160
 no
CYP2C19
2141
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
P-gp
1932
 no
UGT1A1
303
 no
CYP2B6
1160
 not expected [IC50 2.8 uM]
CYP2C8
1117
 not expected [IC50 30.1 uM]
OCT2
782
 not expected [IC50 8.24 uM]
OAT1
730
 not expected [IC50 >100 uM]
OAT3
749
 not expected [IC50 >100 uM]
CYP1A2
2333
 not expected [IC50 >25 uM]
CYP2C19
2141
 not expected [IC50 >25 uM]
CYP2C9
2497
 not expected [IC50 >25 uM]
P-gp
1932
 weak [IC50 22.5 uM]
weak (co-administration study)
Comment: increased Cmax of digoxin by 41%, increased AUC0-inf by 8%
Page: 61,63
BCRP
985
 weak [IC50 59 uM]
CYP3A4
2633
 weak
CYP3A
317
 yes [IC50 0.03 uM]
UGT1A1
303
 yes [IC50 16.3 uM]
MRP4
345
 yes [IC50 20.7 uM]
CYP2D6
2546
 yes [IC50 9.2 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
697
 yes
CYP2D6
1388
 yes
CYP3A4
1946
 yes
P-gp
2052
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:72291
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:72291
ChemicalBook
CB62627692
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB62627692
MolPort
MolPort-035-395-741
https://www.molport.com/shop/molecule-link/MolPort-035-395-741
Selleck Chemicals
cobicistat-gs-9350
http://www.selleckchem.com/products/cobicistat-gs-9350.html
ZINC
ZINC000085537014
http://zinc15.docking.org/substances/ZINC000085537014
PubMed

PubMed

TitleDatePubMed
Pharmacokinetic enhancers in HIV therapeutics.
2014-10
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.
2012-10
Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
2010-11
Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.
2010-08-12
Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.
2010-03
Patents

Patents

20080108617
1
20080207620
1
20090093467
1
20090093482
1
20090181902
1
20090291952
1

Sample Use Guides

In Vivo Use Guide
TYBOST (cobicistat) (150 mg orally once daily) must be coadministered with atazanavir (300 mg orally once daily) or darunavir (800 mg orally once daily) at the same time, with food, and in combination with other HIV-1 antiretroviral agents
Route of Administration: Oral
In Vitro Use Guide
HIV infected monocytic (U1) cellss were treated with 2 uM Cobicistat as a booster drug for 5 uM elvitegravir.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:03:27 GMT 2025
Edited
by admin
on Wed Apr 02 07:03:27 GMT 2025
Record UNII
LW2E03M5PG
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
COBICISTAT
DASH   INN   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
EVOTAZ COMPONENT COBICISTAT
Preferred Name English
COBICISTAT [JAN]
Common Name English
STRIBILD COMPONENT COBICISTAT
Brand Name English
(1,3-THIAZOL-5-YL)METHYL (5S,8R,11R)-8,11-DIBENZYL-2-METHYL-5-(2-(MORPHOLIN-4-YL)ETHYL)-1-(2-(PROPAN-2-YL)-1,3-THIAZOL-4-YL)-3,6-DIOXO-2,4,7,12-TETRAAZATRIDECAN-13-OATE
Common Name English
REZOLSTA COMPONENT COBICISTAT
Brand Name English
2,7,10,12-TETRAAZATRIDECANOIC ACID, 12-METHYL-13-(2-(1-METHYLETHYL)-4-THIAZOLYL)-9-(2-(4-MORPHOLINYL)ETHYL)-8,11-DIOXO-3,6-BIS(PHENYLMETHYL)-, 5-THIAZOLYLMETHYL ESTER, (3R,6R,9S)-
Common Name English
COBICISTAT, (R,R,S)-
Common Name English
SYMTUZA COMPONENT COBICISTAT
Brand Name English
COBICISTAT [ORANGE BOOK]
Common Name English
GENVOYA COMPONENT COBICISTAT
Brand Name English
Cobicistat [WHO-DD]
Common Name English
COBICISTAT [VANDF]
Common Name English
COBICISTAT [MI]
Common Name English
COBICISTAT [USAN]
Common Name English
GS-9350
Code English
PREZCOBIX COMPONENT COBICISTAT
Brand Name English
1,3-THIAZOL-5-YLMETHYL ((2R,5R)-5-(((2S)-2-((METHYL((2-(PROPAN-2-YL)-1,3-THIAZOL-4-YL)METHYL)CARBAMOYL)AMINO)-4-(MORPHOLIN-4-YL)BUTANOYL)AMINO)-1,6-DIPHENYLHEXAN-2-YL)CARBAMATE
Common Name English
cobicistat [INN]
Common Name English
Classification Tree Code System Code
WHO-ATC J05AR09
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
FDA ORPHAN DRUG 577917
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
WHO-ATC J05AR15
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
WHO-ATC V03AX03
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
NDF-RT N0000191001
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
EMA ASSESSMENT REPORTS GENVOYA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
LIVERTOX NBK547911
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
NCI_THESAURUS C471
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
WHO-VATC QV03AX03
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
WHO-ATC J05AR18
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
EMA ASSESSMENT REPORTS EVOTAZ (AUTHORIZED: HIV INFECTIONS)
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
WHO-ATC J05AR14
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
EMA ASSESSMENT REPORTS STRIBILD (AUTHORIZED: HIV INFECTIONS)
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
EMA ASSESSMENT REPORTS REZOLSTA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
WHO-VATC QJ05AR09
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
Code System Code Type Description
DRUG BANK
DB09065
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
NDF-RT
N0000190107
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]
RXCUI
1306284
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY RxNorm
ChEMBL
CHEMBL2095208
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
DAILYMED
LW2E03M5PG
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
NCI_THESAURUS
C97360
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
EPA CompTox
DTXSID00143269
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
NDF-RT
N0000182137
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
NDF-RT
N0000185503
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY P-Glycoprotein Inhibitors [MoA]
NDF-RT
N0000190113
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
SMS_ID
100000127699
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
PUBCHEM
25151504
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
MERCK INDEX
m3706
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY Merck Index
INN
9266
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
WIKIPEDIA
COBICISTAT
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
CHEBI
72291
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
FDA UNII
LW2E03M5PG
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
NDF-RT
N0000190114
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
NDF-RT
N0000190108
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]
CAS
1004316-88-4
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
EVMPD
SUB33760
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
IUPHAR
7535
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
DRUG CENTRAL
4299
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
USAN
WW-13
Created by admin on Wed Apr 02 07:03:27 GMT 2025 , Edited by admin on Wed Apr 02 07:03:27 GMT 2025
PRIMARY
Related Record Type Details
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
IC50
CYTOCHROME P450 1A2
METABOLIC ENZYME -> NON-INHIBITOR
IC50
OAT-2
TRANSPORTER -> NON-INHIBITOR
IC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
TIME-DEPENDENT INHIBITION
IC50
CYTOCHROME P450 2B6
METABOLIC ENZYME -> INHIBITOR
INHIBITOR
IC50
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
OCT-2
TRANSPORTER -> INHIBITOR
IC50
OCT-3
TRANSPORTER -> NON-INHIBITOR
IC50
MATE-2
TRANSPORTER -> INHIBITOR
IC50
CYTOCHROME P450 2D6
METABOLIC ENZYME -> INHIBITOR
IC50
COBICISTAT ON SILICON DIOXIDE
SUB_CONCEPT->SUBSTANCE
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
INHIBITOR
IC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
TIME-DEPENDENT INHIBITION
k(inactivation)
CYTOCHROME P450 2C9
METABOLIC ENZYME -> NON-INHIBITOR
IC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
TIME-DEPENDENT INHIBITION
IC50
CYTOCHROME P450 2C19
METABOLIC ENZYME -> NON-INHIBITOR
IC50
CYTOCHROME P450 2C8
METABOLIC ENZYME -> NON-INHIBITOR
INHIBITOR
IC50
Related Record Type Details
Structure of BIS(THIAZOL-5-YLMETHYL)CARBONATE
IMPURITY -> PARENT
Structure of HYDROXY COBICISTAT
IMPURITY -> PARENT
Structure of 5-THIAZOLYLMETHYL N-((1R,4R)-4-(((2S)-2-AMINO-4-(4-MORPHOLINYL)-1-OXOBUTYL)AMINO)-5-PHENYL-1-(PHENYLMETHYL)PENTYL)CARBAMATE
IMPURITY -> PARENT
Structure of C,C?-Bis(5-thiazolylmethyl) N,N?-[(1R,4R)-1,4-bis(phenylmethyl)-1,4-butanediyl]bis[carbamate]
IMPURITY -> PARENT
Structure of 5-THIAZOLYLMETHYL N-((1R,4R)-4-AMINO-5-PHENYL-1-(PHENYLMETHYL)PENTYL)CARBAMATE
IMPURITY -> PARENT
Structure of N-METHYL-N-((2-(1-METHYLETHYL)-4-THIAZOLYL)METHYL)-N'-((3S)-TETRAHYDRO-2-OXO-3-FURANYL)UREA
IMPURITY -> PARENT
Structure of (2S)-2-((METHYL(((2-(PROPAN-2-YL)-1,3-THIAZOL-4-YL)METHYL))CARBAMOYL)AMINO)-4-(MORPHOLIN-4-YL)BUTANOIC ACID
IMPURITY -> PARENT
Related Record Type Details
Structure of COBICISTAT
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966